Stifel analyst Paul Matteis maintains $Neurogene (NGNE.US)$ with a buy rating, and adjusts the target price from $44 to $46.
According to TipRanks data, the analyst has a success rate of 39.5% and a total average return of 2.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Neurogene (NGNE.US)$'s main analysts recently are as follows:
The stock is currently trading "near cash" following the company's disclosure of a Serious Adverse Event in its NGN-401 high dose trial, along with the termination of the Battens program. Despite these issues, management does not anticipate a clinical hold after discussions with the FDA, noting the safety of the low-dose treatment.
The revised outlook for the shares reflects a model update for the third quarter of 2024 and considerations regarding the status of a trial participant who was critically affected after receiving a high dose of NGN-401. The adjustment in expectations also accounts for a reduced forecast of the market share for the Rett syndrome gene therapy, specifically NGN-401, now estimated at 50%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Paul Matteis維持$Neurogene (NGNE.US)$買入評級，並將目標價從44美元上調至46美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.5%，總平均回報率為2.2%。
此外，綜合報道，$Neurogene (NGNE.US)$近期主要分析師觀點如下：
繼該公司在其 NGN-401 高劑量試驗中披露嚴重不良事件以及終止巴頓計劃之後，該股目前的交易價格爲 「接近現金」。儘管存在這些問題，但管理層在與美國食品藥品管理局討論後預計不會暫停臨床治療，同時指出低劑量治療的安全性。
修訂後的股票展望反映了2024年第三季度的模型更新以及對在接受高劑量 NGN-401 後受到嚴重影響的試驗參與者狀況的考慮。預期的調整還導致對雷特綜合徵基因療法（特別是 NGN-401）市場份額的預測降低，目前估計爲50％。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
